Using Tranilast to Enhance Radiation Treatment for Recurrent Nasopharyngeal Carcinoma
Application of Tranilast as a Radiosensitizer in the Treatment of Radiotherapy Resistant Nasopharyngeal Carcinoma: a Phase II Clinical Study
PHASE2 · Nanfang Hospital, Southern Medical University · NCT05626829
This study is testing if adding the allergy medication Tranilast can make radiation treatment work better for people with recurrent nasopharyngeal cancer.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 18 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05626829 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Tranilast, an anti-allergic medication, as a radiosensitizer to improve the effectiveness of radiotherapy in patients with recurrent nasopharyngeal carcinoma. The study aims to enroll patients who have previously undergone standard radical radiotherapy and chemotherapy but are experiencing recurrence. By inhibiting tumor-related fibroblasts, Tranilast may reduce resistance to radiation therapy, potentially leading to better treatment outcomes. The trial will assess the safety and efficacy of Tranilast in this specific patient population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with recurrent nasopharyngeal carcinoma who have previously received standard treatment and are not candidates for surgery.
Not a fit: Patients who are unable to take oral medication or have known allergies to Tranilast may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates for patients with recurrent nasopharyngeal carcinoma.
How similar studies have performed: Other studies have shown promising results using radiosensitizers in cancer treatment, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Sign informed consent 2. At least 18 years old on the date of signing the informed consent 3. Previously received standard radical radiotherapy and chemotherapy 4. Recurrent nasopharyngeal carcinoma in situ or cervical lymph nodes confirmed by pathological biopsy and imaging examination 5. After multidisciplinary consultation, there was a clear indication for surgery, and the patient was informed and refused to accept surgical treatment 6）ECOG PS：0/1 7) Laboratory examination confirmed good organ function, which should be carried out within 10 days before the first treatment. Exclusion Criteria: 1. After evaluation, it does not meet the indications of re-radiotherapy 2. unable to take oral medication 3. Pregnancy or lactation 4. Known allergy to Tranilast 5. Patients who are judged by the researcher as unsuitable to participate in this trial
Where this trial is running
Guangzhou, Guangdong
- Southern medical university — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Principal investigator: Guan Jian, Ph.D. — Nanfang Hospital, Southern Medical University
- Study coordinator: Guan Jian, Ph.D.
- Email: 51643930@qq.com
- Phone: +86-1363210224
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Nasopharyngeal Carcinoma, Recurrent Cancer